Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion
Swedish Orphan Biovitrum gains a boost to its US commercialization infrastructure, a product to make immunology a key part of its specialty care business, and financial flexibility to seek further product acquisitions, through an RSV products deal with AstraZeneca.
You may also be interested in...
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.
Swedish specialty pharma and rare diseases company seeks to sustain recent rapid revenues growth with increased R&D focus and investments in its hematology and immunology franchises.
At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.